Berman Capital Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Berman Capital Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Buy	+273	New	+$2.34K	﹤0.01%	2003

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's PSTX Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2021: 273 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2003 among its holdings.

65 funds tracked by Wall St. Rank hold PSTX as of Q3 2021.

Berman Capital Advisors held 273 shares of Poseida Therapeutics, Inc. Common Stock worth $1K as of Q3 2021.
Poseida Therapeutics, Inc. Common Stock was a new Berman Capital Advisors position in Q3 2021.
Poseida Therapeutics, Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2003 holding.
65 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.